HUE031995T2 - Készítmények és eljárások szklerosztin elleni ellenanyagokra szolgáló alkalmazásra - Google Patents

Készítmények és eljárások szklerosztin elleni ellenanyagokra szolgáló alkalmazásra Download PDF

Info

Publication number
HUE031995T2
HUE031995T2 HUE13151551A HUE13151551A HUE031995T2 HU E031995 T2 HUE031995 T2 HU E031995T2 HU E13151551 A HUE13151551 A HU E13151551A HU E13151551 A HUE13151551 A HU E13151551A HU E031995 T2 HUE031995 T2 HU E031995T2
Authority
HU
Hungary
Prior art keywords
antibody
ser
sclerostin
gly
antibodies
Prior art date
Application number
HUE13151551A
Other languages
English (en)
Inventor
Michaela Kneissel
Christine Halleux
Shou-Ih Hu
Beate Diefenbach-Streiber
Josef Prassler
Original Assignee
Mereo Biopharma 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40219404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE031995(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mereo Biopharma 3 Ltd filed Critical Mereo Biopharma 3 Ltd
Publication of HUE031995T2 publication Critical patent/HUE031995T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)

Claims (7)

  1. éseljárások sxklemjaim ellent eilííianyagokra ssxolg&amp;tá alkátaítsásrsi §£8h«08 Inti!gí8$'!>«»«0 k I, izolált ellenanyag vagy aaligénkötö tésze. aatxal jdtemm-e, hogy a?, ellenanyag vagy antigénkoNN Öve speoilíkustiít kOtOOIk sekNotsOm goKgeptklhe:··:, vb ««lube»;;: (aj egy f.ORI nehé&amp;Ünc variábilis. régink amely reieben;:·: így SbQ ÍV.í NO; 4 neerini xttbk vette iáböl Ilid atpioosttv-sxekveste iák (¾} egy <'DR2 nehéxlábe variábilis régük, amely tartalmin: *gy SEQ1D NO: 15 szerűm aeekveeciáboii: pld aRííno^v-szekvíitciílt; t,c' cvj <. PR* aebe'kmc v85! *ΙΌν <eg50k amel\ ^wíbü? vg> bit/ IP NO 26 -ív‘í<05! ssek-venesabot állá nminom-saekvenciát; (dt egy ODRI kiimtyülánc variábilis re dók amely tartalma?. egy SI;.Q IP NO: 37 s?ermíi s?eva vette iából álló amÍ£!»S3¥-S?íkV8r*dáU {&amp;} egy CDK2 könnyülásc vat labilis téglák antoly tartalma* így Sl;Q IP NO: 48 s?ermü s?ekve«et3böl állá .amltis>sav»á*®k-vmetáíj ás íj) e«\ i l)R^ kbnmaláik sambii», scgOt, amely tastalma? egy MK>.IU NO:.59 Süírnm vmkseiteiábö: álló urmrtosav-s-áskvent: iái
  2. 3. Αχ 1. igénypont a&amp;rint* ülennnyag vagy antigénkoíö réssé, stxxnl jellemezre, hogy a,» el tananyag. '. < ·. m i'! 4oh: sn\?e 0 nNi <"»„ e <>·κθ·»ο> í 'Μ-ΟΙ e- eJOmovebNea iö!i pM-Ml ssaesoovahb kjretOkn kbtikhk a ssádv'msxlin poUpepsIdhe·?. í Λ - x’km iái, ' r,N tok k<i ík uN ^ n > >.' cí itoog yp.x mOjesikölö re*?e i**»t jeiieoRsve, hogy ta ellenanyag vagy anugénkftrt rés?n Áralapú Wni-sztgoaluáeios vtxsgáj$ibp1#pbs blokkok» a sxkierosxtm gátié hatását. i a 3 igénypont ellenanyag vagy antigénkotö része, arral jellemezve, bogy a? eliemiayag y,sg> atmgénkbm részé IC^-értélie s;4.ler»\?b« jelenlétében. HRKiNO sejt vonaton sejtalapá WaKszignaiszxscibs xiíveálatbm n.A w kisebb, ítioij tgM, oiOmvWn Msebb, «vmt Uíü »M vSí oRovík-oOhn kisebb, «ont 20 nM v 4? <ΛΝύ ,ν>Λ upo; tok ΝοοοΛ íO y^üííts oHooanyof y<5gx ,«tt>ge«kos6 !es,<t, aí*»l jelVm^yv, hogy 82 slleoanyag vagy an»g««k»?6 tésxe seR8lapö,mmer.alÍ2^etós.víjsigá}»!ti>an képev blokkohsi a sikiemsiaist eátk> listását, í. Λ.<: 3 igénypont szetinís elleoattvag. vsgy antígenkmo ratöxy jallomexvs, hegy ;s.-' ellen anyag vágy aotifáRlhll MC-UO sejtekbe», BMP2· ktdykáka injoemlizácnN viesgáintban mém·. kevesebb, tnint ϊμΜ; előnyösett kevesebb, «tini 500 nM és e!öny<J?ebbcB kevesebb, iínnt 200 tsM.
  3. 7. Ak eibzö igét-ypoatok bártnelyike .etetint; ciienenyag vagy anngínkötö resxe, amety gátolja a/ l-.RPON-íklerosatin kölnsenlnnást eklá.s -gái Ián vsvsgálatba;:. S; Á ‘h Igénypont sxennu elíenanyag vagy antseenkOto vésxe, mdyaek US..·-értéké I RPŐ/Síkiemsni». RLInA viasanksösl: tners'e kx'\es,nb, .nts;: taM eioroestn í,evv\,''b, ',»«}· ign ,.\t ek'»>os^»'be» kevesebb',. Haul } o nM, )'<vö;v'l.sben \cví bt;, nnaí á »M, vlönyo eblvn kese ->4sb, nőni > «Μ, feámu%tke smutfl slíbMysf^y -míigéakbtb réssé, üm<-ly képes btokkoisn isssföriiádén* gyakomís gátló hatását 8φ0ορό futskoloMl» v Issgálid bkít 0 \ ' k-N* \n -< v ÍK v „? t\si u >7 &amp; tmé KéH* éve, * v s K „ Nhv '< \ f(v, * íséj^sata:- SM£fceS?na«l:t ihm'müá&amp;iú vtsagsdodsan ke:>\ ·*Μ> tm«t ΙμΜ, cKyro.'W*' |síi:*í«ssSfet miét 500 uML atébyAseo kevesebb. min? 200 s:M. H. ás ÍKÍ0.:lpísjp5ibök báNnelgika ssatMi «iaottayag vagy aodgébköíb mse, arndy tartalmas: dy;m VH tmiipe|»lb»sekvetidák emdy legalább 97>h-^s asotm a SEQ ID NO; ?<) ssodat! szekvenciával.
  4. 12. As H i. Igéstypot-takbármelyike ssedítii: efetsaya® vagy aíaigJeMdl mse, asedy tartalmas olyat! Vb poltpepild^sekvemááh amely legalább 0 í%-0a·* assmos a SHQ ÍD NO; 11 SvSenmLszskvemdávai. ö. As 1-12. igé^ypessíték:bárme!ylka asedrtii ellsssayag vagy aodgáskbibxmm, ama!y taNalmsa olyas VI,. pöiipOpiiO^zéksesélát. smaíy legalább 91%-btm ásom» a S.EQ ÍD NO; k 1 szedőd xsekvesdávai és olyas VH pídigeptiíbseekvesdák amely legalább p/bá-han asobOVS SH£> ID NO; ?Ö szerinti szekvenciával. í4 As i 1 * >e.>m$íonink luomhAv ssroHi «tlsnanv&amp;g vagy asttigósíkétb » s<\ »md* SArtal kas ot\« * nil ^ v sv >s»nt eu\.m v t .· 'vr\ k«v. x a, <mtv iegtsteb towbas «xanot < Vft> w> *' Vvt * saslsSíOiáSíO:.·
  5. 15, As 104. tsi&amp;typotuok bármelyike vedrai dkatatyag vagy astlgénkötö tOkaeyasssiyAa^teaa íliyas díjas hosasödgá hótmyölánc-pmimísavszskveíKsót. emeiv Iggslább 05%-ba;>. ásom» a HBQ .......NO: 125: sserittü szt k vem; iá va 1. IÁ, As 105. kása pontok bármelyike s sert fits slk>s?s*yagvagy astsgéjikOfeóOza^aamíy taíOfess^öiyas; :é&amp;m3áM$é·· Wtm0tö®&amp;Miíkmm!$3étwmM&amp; mtady legalább bSávbas vSMOs; a :MW® W NO; 125: olyan tg§M: IbosssOságö Áé^i-baO: a®omn a ShQ 10 NO; 1 M a»·? lm; ^sekversesávai. }?. A* 105 igénypontok báie-ídvike vcrimt lilfe?*atpi:g:; iytsgy: antigénköté sássá, amelysál: saldetoz/tjnhoa kosédexét legalább eg>, !o, igénypont veriíib eH$nanyag vagy aoj-ak aiKigénkoié mse kefvsiSbk'ikkíílsa.
    10. A ί?. I-.:-0iVpoo: <-ív- i!;íi elk-ssmyag. vaj» snogeskótg reaae. ahol a keresatblokkoiávra való kepssssg :-vagy--a·Knmslblok&amp;oltságra vasé képe^-s-sS? Hi,-VsO:e vkagáiat vagy HÚSA vOsgái.%: által xan kimutatva. 0. as vlO?b igém pontok bármelytkv s.aörtníi elknauyag vagy arsíigénkötö s“v'S!7, ahol as vlSenaayag vagy: gatigárskóté sbs/v o-siaokloo-sbt. eikusavag. adott ewtbcss humSu maaokloaslis elk-SKsnyag. 5o. á.í eioso lyéstyposus-k batsnohlke amitm eHemsuyag vagy atttigórtköiö réaso, ahol as sntigeakptp .' .-1 *nab«.ss bab, í íopO. Fv \-.így svl-'v tragsavtuamon 5? Λ a iOO. igénypontok barmelyika sss'd:?ií eika&amp;aysv. vagy snttgéítköíd téazí?, gyógymakeat to?1éaé isíkabxiáaái-a. 22. A? ! -.:t; sg^nypotttok Paoaelylka «end!'kíkuattyag vagy aotlgénkété té&amp;sc. yskisrosktia áll»i kasvetítao patoiogO.; ;eadelki»s.;.ég vagy *skibi'MSla a;neikeéek asía§eveí kapcsolatos ptoibgiáé: mníleiienessóg, pékklal csonths's kaposotédó bekgsó§5 plb&amp;ipl osststiposlkis U$mMi>ibea iőneab alkaítbaaásttt.: .11 As 1-20. löé«y]»)::ksk bánaolylke ssariati olienstnyag v?»íy· á?|ti|áskpto rcsiknek alkaímasáaa síkktxnsu'tt állal kösvdlklt potolögiás modelfeneiság vagy ssidorosstit; emelkedett asiíitioyéi ksgxsoiattn pataiéglss randalkiiesség, péid^ií csodbas kapcs?>!ódö botegacg, példán! oszteoporósb kesOésébm: titíléob aikitnósésra: sáVlplo gy ógyssek gioi|!®sáí&amp;, '!&amp;. ámiot» eikasayag vagy anogdaköds msaa&amp;:oA xísgkatáíöKok stkdfíoósösía vagy: 23. tgénypeot szenttti alkalmasán. ahol a ««snbw ksp^ískidé l^í^pég s kövátkezdtóitariálmszi ssöftortból vs« kiválóivá: el$»Vllégéá;és másodlagos oxsteoporös'.b* osiié^eaesk iapsfead avasakotárís nekróm, mm sísilepnektósk, söf<^ év imgdtóiÉiír gyógyulása., belMlye s iogása#: ds esspólmplantátomokai és egyek kóveíkeléfes IsélöYsIkgK# &amp;mátmmM&amp;, példád Ilid t*£$#ssek sókkal vagy a*tmis*»tt össaeffeggé < s*m*yesasá*.
  6. 25. Gyógyászati készítmény, amely tartalmaz I '30- Igánypsotok Amelyike saerfmt pltesasysgor vagy? agfil 'aatogérdidtó részé? «*» eg> vagy több gyógyászaidig elfogadható negódunypgöu higito? ysígylppfedk. '0 A > sgí. "-po? ! X'fi·' i P'-Pppv"' sO SV-ZS! ' 0 "t vOX'k í'uxd' ^)AW>4'sít s*. n> nlnsav d' Uoialí pOsod íc5.'í'd",\k^cncKí. >m ,Κ l-,'ό iges-viOnx-k ksstrJxske \o"usts elk-van'.ngos kídd vagy kíÉSpi: 28 k knave \agy expresszié* veknx, supply dsMdsd egy yggy· 101¾ -¾ jj|#ypd«t szériái polinukieosklot. 3d w ón,, x «me.x tsutehxa* egv vy,<\ !-d->k d χ-,,νννι,; χ,-ννό kd'-v > \,í;n . nsr'-.'N/k·';vAsvi M. Ili ár ás. 1--21. igóaypsX'slok Mrmelyrke vc-slno ellenanyag vagy annak anlgénktHő részesek-etóáliitasáfa, amely magában sbglalja a .ás·. igénypont szelni! gazdasep tenyésztését «»belőle az dlenaayag vagy amigOsskósö d vének izolálás.*·. Id. Az !-.?ö. sgéssypxsníok dinnoidke v.viínd díessussvig vagy ennek anngí.-nköí?' we vagy 25 vagy··5 k< ρν'ίχ,χ.ϊίΐ szetmt' g\óg\..!-a a '•V'-'í. our*, s/Kle» «nzun által közvetítést patológiás ivm-elteneí<s.eg vagy szkiefoszini emelkedőit szmijevd kapcsolatos pmologud teodelkmeiniég k»v,elé«d>en vagy megelözésébe-s íMüjl al kakr· a zás. ra.
    22, Az 1-2(1. sgérsyptmiok bármelyike szerinti eitépárpg' alkalmazás».;· ;l$Mer«s«la által közvetíteti patológiás rendelkmesség vagy sxklröszlg agbíeiksgsit szintjével kapcsolatot:; patológiás rendelienesseg kveiédivn vagy snagvsösésébsx Íörigab alkökrass.áani asölgáié gy%y»2«f «IMlüíásáns.
  7. 33. Diagíioasíjkai ké-zfeg asxdy íariakxas: k-20. ggjtsypomo.k bá!sra;iyik« sssusm* eik'oaayago? vagy »;ak a«t^éxNötöy|sg|s 34. in viúa díárás vsklmsssSsm sspíosszjakx sva vagy n/övsí íszonosiíására, asndy íiuaaa maganaíi íogktija a \,g;a i/v'Ws 'xaPkváK'iVa^; i-3-3 psauok barnsciyikc >aía'Hki sikaiarisaggd a,;gy ,ans?k <! ,Vfí^gí.o K‘\ <··.í. í v v ,i- 'vág s f\ av'xk níuí\.>ion a u n! <! x a'nxsk!*( ív n kei alsói íukíti vaolhcn a vknko mddaakv, ilaofvvzcsns, víágficws, ρ&amp;ονηνgoeses vagy ka'miksnnosvvcvsis 35 As i 20 gésv; (V'van'd VanavkAv a/cnnü alien,anaag vas a arasgeok^kt ua?o ös sA ,'oicdionvav, |as ΪΓ'dkki vkuvnaag, ind akoJrorák ?>as avo-i kP4 vHanaovstg p> kí3di ,xs,x\ xsϊ* 'aioitaw'· isíazáWko aíiyags poldiöi kaicdíikum, ssi}o«s«s.iifi sikai k<m«tlseti psoiögsás ívjdeikünaaég vagy szkJerosaáia «mfeikedett színijével kapcsolatos patológia* teodelksiesség kovaíéaóbcn torténö alk^njazáyra. x \ t 20 pviVtOívnok I %s kíA '-ni u í <.,*£ v»>\ an> <.n\ ίΡ «a .s'» >' A‘ ’v>"> t ^ ' ívDKkI o leo&amp;ovag, tliA aknxdfoas:, t»xi »as l KIH dívna <\ <gi svs hl’d! tevagv ívs' '\* η!κ«?*«'«! tek,\»badno anysg pv'idaol k k'.ksokasn dWkon.asv,askk-u^sSio ak.d \A,'v„nxu. pattxogíassonpakonosvvg vsxgy sskk-roszoa toxelkcdíAt szimjévd LspcsdaKA psaoiogjóv rendellanassvg kvsed.xkié;: ióíténo ídkaiinosisaip szolgáló gyógysrer elóidluássra. X t ' >> ' ' 1 iK \ N Í dg»' V Jgy »v ' tk «' bb. 'SOOX ' v'N Vs \ X ,. <·> tiO ΐΐ’είί] kta vetített patokvdás nmiteiienx'ssif vagy sakkismais ©nse&amp;edtft smtjévet kápesokxtoa |<atoU1&amp;táá: tetKktkn'wég k$^-k^éfcsn Attend alkaímaapsm*éá baítodytkévd együtt van aikalnt&amp;svo: (0 aaMtftsasav, (ii) adÍ4ME;l bstf^&amp;pyag, (Hi) aisodswtlb (ív): wi--I RP4 ölleítattyag, ív', hpi"H év vagy (vu pf^fecMö^rdsa&amp;bsii^^a^ipéypikís&amp;teiHiaam 38 Az IO.t). fénypontok b^)«elyik«i«»intyife»appg vagy •l^i^mün: JHttí kbaveíkab: pakltpás: tvstgy sslttatóM: «ísglkpíkt: ««? kagesolidös patológiás f«n<telk'OVNSég kezelésében tdrtérsb alksikspaásta sadg ák's gyOgyi^f glékitósSíítj dbói sa. eifetsanyag: vagy «ottak antigvokótó rést* a köv^tkea&amp;k bátmelyskévet vgvtks v*o atkaitna&amp;vá;·:(t)^s&amp;lmosgy, pl) etkb-DK KJ dlet-anyag, (bh atcndraeáu pvt antl-lRká «{kőanyag, tv) hl·'ΓΗ és/vsp (yi) anyig* pdkláblíkaiföttibkóto, u> tsj ✓, * í,'< n, tpR vas dkkl « \t' *v a s á&amp;emtm ' -, vs sntiáÜRH oltetnvae, svá bRIB es/vagy (vsj perasltomtott-feicxabatHtö anyag, például kalciltí&amp;ítnu saklsi'oaaid MátkfeetlfeH pstelégtá* «vmdelk'Resséit vagy -uklmsztin «uelkedou sfriotswel fe^ptnlatos paRdblsás •^ndfeHa^^fi^^téséken: tóttértő alkahttaaávta, ahol s gyógyír K?0, igínypotöok Mrmelytkv ssedídf s){ep»?íyagp! vagy aenák amtgénkbiö sVNiéw! együtt van alkalmazva. Uh v /uviltouvtv, (is) antbBKRI ''íivoam jg, (uR afcsxdrnnát, íivS spit IRN dfenasy ag, tv) hRTB lóvagy tvi) pattal avows übkaabadtió asxyjuy például kívkábbhpfsg idkaimasása spkfes'osím állal közvetítet? psbolbgtó'í jx'tvtí. lix*í psscg vagy wkkrosaím· emelkedett kspestdate gPökkgtls r«odvfees>ség kezelésében történik p!kák?taaMsra a^pígáfó gyógyszer dösMiissáfetsp »ia1 a gyégyxxsr Ül tgloypootnk bármelyike Xísmsls ellertikíyaggal vagy apstsk 4;)- ,&amp;?< t ''50, Igénypontok b¾ττt§|y{ké..5!^Π.n{i^:Mte^>iÉ::'3^^, anttgénkötö m?£,. s?ki«tmptt5 IMI közvetített patológiás rsnddl«tes*ég vagy szktosA: gptsílsipk szintjével kapsokdos' ptolégsás s-esxtklkisessóg kdkMsétet töstéitsX sdkaJt?>az4st«. «kkl s páeksmsek ferákhan Pl zoiedstmssvab pl) ρ«Ρί··ΒΚΒ 1 ekcna«syagsks (ki) ktesIsBnátttí, pv) atsti -l. JM glfekártyagstí, (v> {#11kt k^/vopy i»n p»yaÍ'tem08>tf«teWR»y tnsyagtsp p«lü»kk»l«{Hiik.öm0t;sáüi^:^í.i. 43, 4<a: iüik •jgénv^nt^ kanstglpike sértői) alkttanystg vagy tpígésíktkö yésséstíök tdkalmagása szkkrosatíi áksi kvavvtkvti ptuktgtás randí?ík?tes,vág vagy·' szktervszm miék&amp;útű kspviokPov páíöldgliá mníkMapasség kyavSwvbvts t^tppk agotpio gyégyska? é{#éÖÖ^fct©n?jk4:«i:pfe^S8#· kixttbhm ii) K)iadmapyak au ami-DKR); vUeaasyyagPk (Hu aknUfonátt^ tiv) Mtikjklf4:.l3K4^yÍ^'(#: h.PH-? és?vagy tvi) patpshbns>an'kk/abstkk6 anyagot, pkkbs! kafcibtikttstsííí aatak be, 41, p> /viv4n«\5,,n, (its aiíti-Dk κ l eHeoaoyag. (ns) akodtonat. Px) x«tt-Í R^t düíaaay&amp;g í^4 bkllt étvágy (Vt> ps-stbpnbon-lcKvabadko anyag, pékpul kakálkskum i^kropsia lkai kb^vvtitast patológia* fpadallettex^ég vagy s«k{#o*<tto vinílkvdctt s/tatjéwl kaposökias patológiás (kistélkaossóg ieaeiásóbvtt (Öttkné aikalfbsaáap aboí % páeietssóak kofákban P20. igknypóíitok báttnai>ik* saböktl elknanyagot adtak ba. vapx asstxok atipgyoMo tva/vi adták Ív, 44, ti) ZokSkötnav, <»j antkDKKl eHenanyog, pH) slestdrooái, (;v) ttab'-l.kpd elktnmyjxg, {>·) ηΓΪΗ ksÁatgy (y|j pstxsihöibxon'dblsifabíidiiP anyag, ptddatd kalvilttilutm ttlkalrneaase s/kleros^tbt által koavetitett patpibgsás tvndvtknasség *ag\ *íkUros^ttn envlkadap, ..sKtntjével kapcáoíalos pasolbgisk tx-ntlelU'n«íá,«<fg keasiésébeft torkod alkalmazásra szobit gyógyír* oloSHHlbahas, s kiadhass * -! igísoímnoá; bármelyike si'vnms oíloírmy«gbt *í<li^s. bt' w>gy -otnak aokgookoto rSssá» «üuk bt'. ..Js Λ *ς V; 4 XQ % 4 { ν*ςγ A'i. 4££ftS>mí .Utíridd <jH«SÖáy»g Vágj &amp;«S«4k <m»gC«h6K* ís'*ív? V%’> Uí iO'-etbo^Sst üd s(K* Okk t OOimpotsig 0í!* .>hf»K5{Vfiáh ÍO í 440'! kk* «ΟΟΟ,ΟΟΟΌ ít < hl III í·-, \Λ·.Λ V'l* ftöraihi*Hfcö8-&amp;!s<r»b8ri!ti&amp;·royqgu pékfetoí kwft&amp;sk-um, a* sál siaghaláFpl&amp;ítt áskai&amp;áSEásf<k v&amp;gy a ?(>., ?b·; '>&amp;> 42 v«gy 44. Igány poíií m-rmd aSkalmarás, <shs>l a hPTl I hP111{ I 34). 46. A 3$ . 3? . 30, 41 vagy 43. igáoypom sisrhbi díarsovtg vsgy sokak amlgáiíkíáö fí;.a<·. vagy u) isO &amp;m Okki í4b"i..'5í íg, yas «RnkKk.k. ολ' ooo I Rn (.lUo.ovvog <v> hl'iH vo'a vtó f&amp;sxishmxmm4s4s2.<4\aiiíd anyag, pákkkb katcikiíkkm az olt moghMárfXsmt aikalmötásití, vagy a 36 . kik, 4(1,, 42 \x-.gv 4 4 igei»', {X ni ϊί'ί,ϋ-ΐΐϊ ab a ka í*a,\ anol 4 cvniia.1 kapós ohtoa ss'íuk'ílbüC^vg 4 kö\< d ext'k \o/u. k'gaObl' agy seodelk-nrsvás;· fkódk'gas ás másodlagos. os.OíxgK'ít'lrk, tíszieopán;». osshíoímáíkkk osíöogssfciih . imparievta ava-xám'áns íkAxoíos. a&amp;tz osskoa'kröxi», -ívnjs <?* ímplatoáíum gtogyaiksa, holaéftve a fogászai i (s csígösmpkiSiSáiaojíÁsí, ogyáb ssndeSlsns.ssog kovdkarkbxm hekövsttkozó cíontvesxti.'?, páUláal HIVAkmáxásss:;, rákkal vagy amlíAs/d bsszOtlggá csontve-s/kv
HUE13151551A 2007-10-12 2008-10-10 Készítmények és eljárások szklerosztin elleni ellenanyagokra szolgáló alkalmazásra HUE031995T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07118414 2007-10-12
EP08151911 2008-02-25
EP08161342 2008-07-29

Publications (1)

Publication Number Publication Date
HUE031995T2 true HUE031995T2 (hu) 2017-08-28

Family

ID=40219404

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13151551A HUE031995T2 (hu) 2007-10-12 2008-10-10 Készítmények és eljárások szklerosztin elleni ellenanyagokra szolgáló alkalmazásra

Country Status (36)

Country Link
US (3) US7879322B2 (hu)
EP (2) EP2203478B1 (hu)
JP (3) JP2011502470A (hu)
KR (2) KR20130029452A (hu)
CN (1) CN101821291B (hu)
AR (1) AR068767A1 (hu)
AU (1) AU2008309514B2 (hu)
BR (1) BRPI0817879A2 (hu)
CA (1) CA2702005C (hu)
CL (1) CL2008003004A1 (hu)
CO (1) CO6270368A2 (hu)
CR (1) CR11313A (hu)
CU (1) CU23869B1 (hu)
CY (2) CY1114872T1 (hu)
DK (2) DK2203478T3 (hu)
EA (1) EA018756B1 (hu)
ES (2) ES2614328T3 (hu)
GT (1) GT201000085A (hu)
HK (1) HK1143173A1 (hu)
HN (1) HN2010000674A (hu)
HR (2) HRP20140161T1 (hu)
HU (1) HUE031995T2 (hu)
IL (1) IL204510A (hu)
LT (1) LT2586796T (hu)
MA (1) MA31760B1 (hu)
MX (1) MX2010003915A (hu)
MY (1) MY152282A (hu)
NZ (1) NZ584158A (hu)
PE (1) PE20091221A1 (hu)
PL (2) PL2586796T3 (hu)
PT (2) PT2586796T (hu)
SI (2) SI2586796T1 (hu)
TN (1) TN2010000140A1 (hu)
TW (1) TWI489993B (hu)
WO (1) WO2009047356A1 (hu)
ZA (1) ZA201001789B (hu)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2628116A1 (en) 2005-10-31 2007-12-13 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP3345607B1 (en) * 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
WO2010037041A2 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2011037791A1 (en) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
BR112012028920B1 (pt) 2010-05-14 2021-03-23 Amgen Inc. Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
US9403882B2 (en) 2010-06-07 2016-08-02 Joshua Rabbani Sulfation of Wnt pathway proteins
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
US9493541B2 (en) 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
US11167011B2 (en) 2010-06-07 2021-11-09 Enzo Biochem, Inc. Methods for treating bone loss using sclerostin peptides
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP2632951B1 (en) * 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use
EP3757126A1 (en) 2010-11-05 2020-12-30 Novartis AG Methods of treating psoriatic arthritis using il-17 antagonists
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
MX2013010011A (es) * 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
PL3404041T3 (pl) 2011-04-19 2020-12-14 Amgen Inc. Sposób leczenia osteoporozy
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
HUE039786T2 (hu) 2011-08-04 2019-02-28 Amgen Inc Csonthiány-defektusok kezelési módszere
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
CN104203978A (zh) * 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
US9803009B2 (en) 2011-10-24 2017-10-31 Abbvie Inc. Immunobinders directed against TNF
UY34410A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
RU2014122602A (ru) 2011-11-04 2015-12-10 Новартис Аг Конструкции на основе белка, родственного липопротеинам низкой плотности, 6(lrp6), и удлинителя полупериода существования
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en) * 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP2016501230A (ja) * 2012-11-29 2016-01-18 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体
CA2892748A1 (en) 2012-11-29 2014-06-05 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein c and uses thereof
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9708375B2 (en) * 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
SI3312195T1 (sl) * 2013-03-20 2020-02-28 Genzyme Corporation Postopki zdravljenja osteogeneze imperfecta
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
RS61158B1 (sr) * 2015-03-13 2021-01-29 Jiangsu Hengrui Medicine Co Anti-sklerostin antitelo, antigen vezujući fragment i njegova medicinska upotreba
WO2017087391A1 (en) 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3496744A1 (en) 2016-08-08 2019-06-19 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
BR112019012731A2 (pt) 2016-12-21 2019-11-26 Mereo Biopharma 3 Ltd uso de anticorpos antiesclerostina no tratamento de osteogênese imperfeita
UA126284C2 (uk) * 2016-12-21 2022-09-14 Сефалон, Інк. Антитіла, які специфічно зв'язуються з людським il-15, та їхнє застосування
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3574010A4 (en) * 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
CN108866002A (zh) * 2017-05-12 2018-11-23 上海复旦张江生物医药股份有限公司 用于sost蛋白或抗体筛选的细胞株及其制备方法和应用
TW201909913A (zh) 2017-07-27 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種ｓｏｓｔ抗體醫藥組成物及其用途
CN107817350B (zh) * 2017-10-26 2019-09-06 成都医学院第一附属医院 一种肺癌筛查试剂盒
MX2020010092A (es) 2018-03-30 2020-10-28 Amgen Inc Variantes de anticuerpo c-terminales.
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
CN112702991A (zh) 2018-08-10 2021-04-23 安进公司 制备抗体药物配制品的方法
EP4000633A4 (en) * 2019-07-12 2024-02-21 Kyoto University NEUTRALIZING ANTIBODIES FOR THE TREATMENT OF DENTAL REGENERATION TARGETING THE USAG-1 MOLECULE
US20220275073A1 (en) 2019-08-12 2022-09-01 Amgen Inc. Anti-Sclerostin Antibody Formulations
TR201920272A1 (tr) * 2019-12-15 2021-06-21 Uludamar Altay Dental i̇mplantlar, greft materyalleri̇ ve prf i̇le osseoi̇ntegrasyonun artirilmasi i̇çi̇n bi̇r terapöti̇k kompozi̇syon ve bunun lokal kullanim yöntemleri̇
CN112070678B (zh) * 2020-08-10 2023-04-11 华东交通大学 一种批量蛋白质印迹膜条倾斜矫正和分割方法及系统
KR102472582B1 (ko) * 2020-08-20 2022-11-30 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법
CN113354724A (zh) * 2021-04-28 2021-09-07 蒋青 骨硬化蛋白及其在制备治疗或预防阿尔兹海默症的相关产品上应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6455275B1 (en) 1980-02-25 2002-09-24 The Trustees Of Columbia University In The City Of New York DNA construct for producing proteinaceous materials in eucaryotic cells
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH059615A (ja) 1991-07-01 1993-01-19 Sumitomo Metal Mining Co Ltd スポンジＣｄの回収方法
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1998018943A1 (en) 1996-10-28 1998-05-07 Novartis Ag Method for the oligomerisation of peptides
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP1117774B1 (en) 1998-10-09 2009-12-30 Medical Research Council Method for generating diversity
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US7091323B2 (en) * 2001-04-24 2006-08-15 Bayer Corporation Human TIMP-1 antibodies
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
FR2840910B1 (fr) 2002-06-17 2004-08-27 Rhodia Chimie Sa Composition silicone pour la realisation d'un ensemble comprenant plusieurs elements en silicone reticules par polyaddition adherant fermement les uns aux autres
US20040065598A1 (en) 2002-06-17 2004-04-08 Ross David Justin Address disambiguation for mail-piece routing
CN101899106A (zh) 2002-10-29 2010-12-01 阿纳福公司 三聚细胞因子的三聚结合蛋白
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US20060264576A1 (en) 2005-03-24 2006-11-23 Roelofs Mark G Process to prepare stable trifluorostyrene containing compounds grafted to base polymers
US7737190B2 (en) 2005-03-24 2010-06-15 E.I. Du Pont De Nemours And Company Process to prepare stable trifluorostyrene containing compounds grafted to base polymers using a solvent/water mixture
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP5688829B2 (ja) * 2005-11-11 2015-03-25 敏一 吉川 示差的な糖尿病の予知・診断方法および糖尿病予知・診断用キット
DE102006002221A1 (de) 2005-11-11 2007-05-24 Micronas Gmbh Integrierter elektronischer Schaltkreis
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
BRPI0809026A2 (pt) 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US20110044978A1 (en) 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture

Also Published As

Publication number Publication date
HN2010000674A (es) 2013-02-04
PE20091221A1 (es) 2009-09-11
HRP20170347T1 (hr) 2017-08-11
PL2203478T3 (pl) 2014-05-30
US20110052592A1 (en) 2011-03-03
CN101821291A (zh) 2010-09-01
CY1118691T1 (el) 2017-07-12
TN2010000140A1 (en) 2011-09-26
CL2008003004A1 (es) 2009-06-26
EA018756B1 (ru) 2013-10-30
TWI489993B (zh) 2015-07-01
HK1143173A1 (en) 2010-12-24
TW200922621A (en) 2009-06-01
US20120276591A1 (en) 2012-11-01
BRPI0817879A2 (pt) 2014-06-17
CU23869B1 (es) 2013-03-27
CU20100059A7 (es) 2012-06-29
JP5913181B2 (ja) 2016-04-27
JP2013153757A (ja) 2013-08-15
JP2016121170A (ja) 2016-07-07
PT2586796T (pt) 2017-03-15
ES2614328T3 (es) 2017-05-30
SI2586796T1 (sl) 2017-04-26
EP2203478A1 (en) 2010-07-07
PL2586796T3 (pl) 2017-05-31
EP2586796A1 (en) 2013-05-01
SI2203478T1 (sl) 2014-03-31
KR20130029452A (ko) 2013-03-22
AU2008309514B2 (en) 2011-06-23
CR11313A (es) 2010-05-06
IL204510A (en) 2013-01-31
AU2008309514A1 (en) 2009-04-16
KR20100074271A (ko) 2010-07-01
EA201000559A1 (ru) 2010-10-29
US8246953B2 (en) 2012-08-21
LT2586796T (lt) 2017-02-27
NZ584158A (en) 2011-10-28
MX2010003915A (es) 2010-04-30
ZA201001789B (en) 2011-12-28
ES2448542T3 (es) 2014-03-14
US7879322B2 (en) 2011-02-01
US8486661B2 (en) 2013-07-16
HRP20140161T1 (hr) 2014-03-28
CA2702005A1 (en) 2009-04-16
EP2586796B1 (en) 2016-12-07
WO2009047356A1 (en) 2009-04-16
JP6401196B2 (ja) 2018-10-03
CO6270368A2 (es) 2011-04-20
GT201000085A (es) 2014-03-14
MA31760B1 (fr) 2010-10-01
CN101821291B (zh) 2013-04-10
CA2702005C (en) 2016-06-14
KR101268675B1 (ko) 2013-06-25
DK2586796T3 (en) 2017-02-13
US20090130113A1 (en) 2009-05-21
DK2203478T3 (da) 2014-02-10
PT2203478E (pt) 2014-02-25
EP2203478B1 (en) 2013-11-20
CY1114872T1 (el) 2016-12-14
AR068767A1 (es) 2009-12-02
JP2011502470A (ja) 2011-01-27
MY152282A (en) 2014-09-15

Similar Documents

Publication Publication Date Title
DK2586796T3 (en) Compositions and Methods for Using Antibodies against Sclerostin
KR102121678B1 (ko) β-KLOTHO, FGF 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질
KR101836501B1 (ko) 근육 성장을 증가시키기 위한 조성물 및 방법
AU2015302959B2 (en) Anti-CDH6 antibody drug conjugates
KR20140021589A (ko) 항-fgfr4 항체 및 사용 방법
BRPI0706524A2 (pt) composições e métodos de uso para anticorpos de dickkopf-1
KR20190104158A (ko) 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
CN111989345A (zh) 激活wnt信号传导的多价结合分子及其用途
AU2016378739A1 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
CN110785186A (zh) 用于治疗免疫性血小板减少的方法